Mind Medicine Stock Today
| MNMD Stock | USD 6.47 0.12 1.89% |
PerformanceVery Weak
| Odds Of DistressLow
|
Mind Medicine is trading at 6.47 as of the 18th of March 2025, a 1.89 percent increase since the beginning of the trading day. The stock's lowest day price was 6.24. Mind Medicine has about a 23 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 18th of December 2024 and ending today, the 18th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 3rd of March 2020 | Category Healthcare | Classification Health Care |
Mind Medicine Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company has 75.37 M outstanding shares of which 10.89 M shares are now shorted by private and institutional investors with about 3.9 trading days to cover. More on Mind Medicine
Moving against Mind Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Mind Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Executive President | Miriam Wernli | |||||||||||||||||||||||||||||||||||||||||||||
| Thematic Ideas | (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Pharmaceutical Products, Biotech, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsMind Medicine can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Mind Medicine's financial leverage. It provides some insight into what part of Mind Medicine's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Mind Medicine (MNMD) is traded on NASDAQ Exchange in USA. It is located in One World Trade Center, New York, NY, United States, 10007 and employs 74 people. Mind Medicine is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 478.59 M. Mind Medicine conducts business under Biotechnology sector and is part of Health Care industry. The entity has 75.37 M outstanding shares of which 10.89 M shares are now shorted by private and institutional investors with about 3.9 trading days to cover.
Mind Medicine currently holds about 105.74 M in cash with (79.13 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.71.
Check Mind Medicine Probability Of Bankruptcy
Ownership AllocationMind Medicine maintains a total of 75.37 Million outstanding shares. Over half of Mind Medicine's outstanding shares are owned by institutional investors. These institutional investors are typically referred to as corporate investors that shop for positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Mind Ownership Details
Mind Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Woodline Partners Lp | 2024-12-31 | 1 M | |
| Tri Locum Partners Lp | 2024-12-31 | 820.8 K | |
| Northern Trust Corp | 2024-12-31 | 684.8 K | |
| Charles Schwab Investment Management Inc | 2024-12-31 | 593.4 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 496.7 K | |
| Ally Bridge Group (ny) Llc | 2024-12-31 | 330.3 K | |
| Goldman Sachs Group Inc | 2024-12-31 | 296.8 K | |
| Nuveen Asset Management, Llc | 2024-12-31 | 286.3 K | |
| Bank Of America Corp | 2024-12-31 | 272.9 K | |
| Blackrock Inc | 2024-12-31 | 6.1 M | |
| Commodore Capital Lp | 2024-12-31 | 4.3 M |
Mind Medicine Historical Income Statement
Mind Stock Against Markets
Mind Medicine Corporate Management
| MD MA | Chief Officer | Profile | |
| Schond MBA | Chief Officer | Profile | |
| Maxim CFA | Vice Communications | Profile | |
| Wong JD | Chief Sec | Profile | |
| Gregg Pratt | Chief Officer | Profile | |
| MD MBA | Chief Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mind Medicine. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Mind Stock refer to our How to Trade Mind Stock guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mind Medicine. If investors know Mind will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mind Medicine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Mind Medicine is measured differently than its book value, which is the value of Mind that is recorded on the company's balance sheet. Investors also form their own opinion of Mind Medicine's value that differs from its market value or its book value, called intrinsic value, which is Mind Medicine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mind Medicine's market value can be influenced by many factors that don't directly affect Mind Medicine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mind Medicine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mind Medicine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mind Medicine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.